Neurology Thesis Topics

Neurology thesis topics represent a scientifically complex and clinically consequential area within health thesis topics, drawing graduate students at American universities into a discipline that addresses the diagnosis, treatment, and neuroscientific understanding of disorders affecting the brain, spinal cord, peripheral nerves, and neuromuscular system. Neurology encompasses stroke, epilepsy, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease and other dementias, neuromuscular disorders, headache, neuro-oncology, and the growing fields of vascular neurology, neurogenetics, and neuroimmunology. As neuroscience advances the understanding of nervous system pathophysiology, disease-modifying therapies transform conditions once considered untreatable, and American neurology grapples with workforce shortages and access disparities, the research questions animating neurology thesis topics have never been more scientifically productive or clinically urgent.

Neurology Thesis Topics and Research Areas

The discipline of neurology research spans molecular neuroscience, translational animal model studies, clinical trial methodology, neuroimaging, neurophysiology, epidemiology, and health services research — offering graduate students research environments ranging from cellular models of neurodegeneration to population-based studies of stroke incidence across American communities. Graduate students pursuing neurology thesis topics engage with advanced neuroimaging analysis, cerebrospinal fluid and blood biomarker measurement, genomic sequencing, electrophysiology, clinical outcome assessment, and implementation science frameworks for improving neurological care delivery across American health systems. The 200 neurology thesis topics organized below into 10 thematic categories are designed to be research-ready at American neurology residency research programs, neuroscience doctoral programs, and academic medical centers with comprehensive neurological research infrastructure.

1. Stroke and Cerebrovascular Disease

Stroke is the fifth leading cause of death and the leading cause of adult disability in the United States — making cerebrovascular disease research one of the most impactful and well-funded areas of American neurology. This category of neurology thesis topics addresses stroke pathophysiology, acute reperfusion treatment, secondary prevention, rehabilitation, and the persistent racial and socioeconomic disparities in stroke incidence and outcomes across American populations. Graduate students contribute to understanding both the biological mechanisms of ischemic and hemorrhagic stroke and the health system factors that determine whether American patients receive timely, evidence-based cerebrovascular care.

1. Investigating the mechanical thrombectomy clinical outcomes and functional recovery predictors in American adults with large vessel occlusion stroke presenting in the six to twenty-four hour extended window
2. Analyzing the racial and ethnic disparities in door-to-needle time performance and tissue plasminogen activator administration rates across American comprehensive stroke centers
3. Developing a stroke systems of care quality improvement program for American rural hospitals without thrombectomy capability and evaluating its impact on telestroke utilization and appropriate transfer rates
4. Characterizing the cerebral small vessel disease MRI burden progression and its relationship to cognitive decline and dementia incidence in American adults with lacunar stroke
5. Investigating the blood pressure management strategy — intensive versus standard — impact on hematoma expansion and functional outcomes in American adults with spontaneous intracerebral hemorrhage
6. Analyzing the cryptogenic stroke workup completeness and atrial fibrillation detection rates in American stroke centers using implantable cardiac monitor data linkage
7. Developing a secondary stroke prevention optimization program for American adults with recent TIA or minor stroke and evaluating its effectiveness in achieving evidence-based risk factor control
8. Characterizing the post-stroke depression prevalence, trajectory, and treatment outcomes in American adults using validated depression assessment and longitudinal follow-up methodology
9. Investigating the intravenous thrombolysis safety and effectiveness in American adults with stroke mimics — including complex migraine, seizure, and functional neurological disorder — presenting with acute neurological deficits
10. Analyzing the carotid revascularization timing and outcomes following symptomatic carotid stenosis in American patients across different stenosis severity and symptom recency categories
11. Developing a stroke rehabilitation intensity optimization protocol for American inpatient rehabilitation facilities and evaluating its impact on functional recovery and discharge disposition outcomes
12. Characterizing the cerebral venous thrombosis clinical presentation, imaging features, and anticoagulation outcomes in American adults including COVID-19-associated cases
13. Investigating the patent foramen ovale closure versus medical therapy comparative effectiveness for secondary cryptogenic stroke prevention in American adults under sixty using long-term follow-up data
14. Analyzing the stroke incidence trends by age group and race in American adults and evaluating the contribution of changing vascular risk factor prevalence to premature stroke in younger Americans
15. Developing a community-based stroke warning sign education and 911 activation program for American communities with high stroke burden and evaluating its impact on emergency department presentation times
16. Characterizing the subarachnoid hemorrhage grading system performance and delayed cerebral ischemia prediction accuracy in American neurovascular intensive care unit populations
17. Investigating the dual antiplatelet therapy duration optimization for American adults with recent minor ischemic stroke or high-risk TIA using comparative effectiveness analysis of registry data
18. Analyzing the neurovascular coupling and cerebral autoregulation impairment patterns in American adults with hypertensive crisis and hypertensive encephalopathy using transcranial Doppler methodology
19. Developing a stroke family caregiver support program for American households with a disabled stroke survivor and evaluating its impact on caregiver burden, depression, and stroke survivor outcomes
20. Characterizing the wake-up stroke and unknown onset stroke imaging selection criteria and thrombolysis outcomes in American stroke centers using MRI DWI-FLAIR mismatch methodology

2. Epilepsy and Seizure Disorders

Epilepsy affects approximately three million Americans — making it one of the most common serious neurological conditions — with important research questions about seizure mechanism, antiseizure medication optimization, epilepsy surgery selection, neuromodulation, and the social and neuropsychological consequences of living with seizures in American communities. This category of neurology thesis topics addresses both the biology of epileptogenesis and the clinical and health services dimensions of epilepsy care across American populations.

21. Investigating the sodium channel subunit variant pathogenicity characterization and precision antiseizure medication selection implications for American children with SCN1A, SCN2A, and SCN8A-related epilepsies
22. Analyzing the antiseizure medication comparative effectiveness for focal onset impaired awareness seizures in American adults using a propensity-matched real-world data analysis from electronic health records
23. Developing a ketogenic diet therapy implementation program for American children with drug-resistant epilepsy in community settings and evaluating its seizure reduction and nutritional safety outcomes
24. Characterizing the epilepsy surgery evaluation pathway completion rates and surgical treatment delays in American adults with drug-resistant focal epilepsy using epilepsy center registry data
25. Investigating the deep brain stimulation of the anterior nucleus of the thalamus long-term seizure reduction and quality of life outcomes in American adults with drug-resistant generalized epilepsy
26. Analyzing the sudden unexpected death in epilepsy risk factors and preventive intervention effectiveness in American adults with drug-resistant temporal lobe epilepsy
27. Developing a seizure action plan education program for American adults with epilepsy and their caregivers and evaluating its impact on seizure first aid quality and emergency department utilization
28. Characterizing the epilepsy-related cognitive impairment patterns and their relationship to antiseizure medication load and seizure frequency in American children using neuropsychological assessment
29. Investigating the responsive neurostimulation device effectiveness and seizure detection accuracy in American adults with bilateral temporal lobe epilepsy who are not surgical candidates
30. Analyzing the antiseizure medication adherence predictors and non-adherence consequences for seizure control and hospitalization in American adults with epilepsy using pharmacy claims linkage
31. Developing a telemedicine epilepsy monitoring program for American rural adults with drug-resistant epilepsy and evaluating its clinical outcome equivalence to in-person epilepsy center follow-up
32. Characterizing the febrile infection-related epilepsy syndrome clinical spectrum and immunotherapy response in American children using multicenter retrospective cohort methodology
33. Investigating the cenobamate efficacy and tolerability in American adults with drug-resistant focal epilepsy and evaluating its mechanism of action on sodium channel and GABA-A receptor function
34. Analyzing the epilepsy health disparities — including treatment access, surgical evaluation rates, and seizure control quality — between American racial and socioeconomic groups using registry and claims data
35. Developing an epilepsy self-management program for American adults that addresses medication adherence, seizure triggers, safety, and psychological wellbeing using digital health platform delivery

3. Neurodegenerative Diseases

Neurodegenerative diseases — including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, amyotrophic lateral sclerosis, and Huntington’s disease — represent some of the most devastating and scientifically challenging conditions in neurology, with disease-modifying therapies beginning to emerge after decades of clinical trial failures. This category of neurology thesis topics addresses the molecular mechanisms of neurodegeneration, biomarker-based disease staging, clinical trial design, and the growing array of therapeutic approaches targeting the protein aggregation and cellular dysfunction driving these conditions in American patients.

36. Investigating the lecanemab and donanemab amyloid-clearing immunotherapy effects on cognitive decline trajectory in American adults with early symptomatic Alzheimer’s disease using real-world registry data
37. Analyzing the plasma phosphorylated tau 217 and 231 biomarker performance for Alzheimer’s disease diagnosis and staging in American memory clinic populations compared to cerebrospinal fluid and PET reference standards
38. Developing a prodromal Parkinson’s disease identification program in American adults using REM sleep behavior disorder, hyposmia, and constipation as early biomarkers and evaluating conversion rates to clinical disease
39. Characterizing the genetic architecture of frontotemporal dementia — including GRN, MAPT, and C9orf72 variants — and the genotype-phenotype correlations in American familial frontotemporal dementia cohorts
40. Investigating the alpha-synuclein seed amplification assay performance for early Parkinson’s disease diagnosis from cerebrospinal fluid and skin punch biopsy in American movement disorder clinic populations
41. Analyzing the GBA1 variant carrier Parkinson’s disease clinical phenotype differences and targeted therapy implications in American Jewish Ashkenazi and non-Ashkenazi patient populations
42. Developing a multidisciplinary amyotrophic lateral sclerosis care program for American patients and evaluating its impact on survival, quality of life, and advance care planning compared to standard neurology follow-up
43. Characterizing the Lewy body dementia misdiagnosis patterns and their clinical consequences in American memory clinic populations using autopsy verification and ante-mortem biomarker methodology
44. Investigating the antisense oligonucleotide tominersen safety and tolerability in American adults with Huntington’s disease and evaluating its pharmacodynamic effects on mutant huntingtin protein levels
45. Analyzing the vascular contributions to cognitive impairment and dementia patterns and their modification through intensive blood pressure treatment in American adults with hypertension and white matter disease
46. Developing a caregiver education and support program for American families caring for adults with frontotemporal dementia behavioral variant and evaluating its caregiver burden and competency outcomes
47. Characterizing the tau PET imaging patterns across Alzheimer’s disease and non-Alzheimer’s tauopathies in American memory disorder program patients using Braak staging and atrophy correlation methodology
48. Investigating the exercise intervention effectiveness for slowing motor and cognitive progression in American adults with early Parkinson’s disease using a multisite randomized trial design
49. Analyzing the dementia incidence trends in American adults over seventy-five and evaluating whether cardiovascular risk factor reduction has contributed to declining age-adjusted dementia rates
50. Developing a precision medicine trial design framework for amyotrophic lateral sclerosis using platform trial methodology that incorporates SOD1, C9orf72, FUS, and TDP-43 molecular stratification

4. Multiple Sclerosis and Neuroimmunology

Multiple sclerosis and neuroimmunology address the immune-mediated disorders of the nervous system — including multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and autoimmune encephalitis — with an expanding array of disease-modifying therapies creating a complex treatment landscape for American neurologists and important research questions about optimal treatment sequencing, biomarker-guided therapy, and long-term outcomes.

51. Investigating the high-efficacy versus moderate-efficacy disease-modifying therapy early treatment comparative outcomes for American adults with relapsing-remitting multiple sclerosis using propensity-matched registry data
52. Analyzing the serum neurofilament light chain dynamics as a pharmacodynamic biomarker for monitoring multiple sclerosis disease activity and treatment response in American clinical trial populations
53. Developing a treat-to-target algorithm for American adults with relapsing-remitting multiple sclerosis incorporating MRI activity, relapse rate, and disability progression as treatment intensification triggers
54. Characterizing the progressive multifocal leukoencephalopathy risk stratification and natalizumab continuation versus switching decisions in American JC virus antibody-positive multiple sclerosis patients
55. Investigating the ocrelizumab versus siponimod comparative effectiveness for secondary progressive multiple sclerosis in American adults using real-world registry and claims data analysis
56. Analyzing the aquaporin-4 IgG seropositive neuromyelitis optica spectrum disorder attack prevention effectiveness of satralizumab, inebilizumab, and ublituximab in American clinical practice settings
57. Developing a multiple sclerosis transition of care program for American young adults moving from pediatric to adult neurology and evaluating its impact on disease activity and treatment adherence
58. Characterizing the cognitive impairment prevalence and neuropsychological profile in American adults with multiple sclerosis and evaluating cognitive rehabilitation program effectiveness
59. Investigating the pregnancy and postpartum relapse risk management and disease-modifying therapy safety in American women with multiple sclerosis using the North American Research Committee on MS registry
60. Analyzing the multiple sclerosis health disparities — including diagnosis delays and disease-modifying therapy access — in American Black patients compared to white patients using multi-site registry methodology

5. Movement Disorders

Movement disorders encompass Parkinson’s disease and atypical parkinsonian syndromes, essential tremor, dystonia, Huntington’s disease, and other conditions affecting the voluntary and involuntary motor system — with important research questions about disease mechanisms, symptomatic treatment optimization, and the expanding role of neuromodulation for movement disorder management in American patients.

61. Investigating the subthalamic nucleus versus globus pallidus interna deep brain stimulation comparative outcomes for motor function, dyskinesia, and quality of life in American adults with advanced Parkinson’s disease
62. Analyzing the focused ultrasound thalamotomy effectiveness and safety for essential tremor in American adults who are poor surgical candidates for deep brain stimulation
63. Developing a Parkinson’s disease exercise prescription program combining aerobic, resistance, and balance training and evaluating its neuroprotective and functional outcome effects in American adults with early disease
64. Characterizing the prodromal Parkinson’s disease cognitive and non-motor symptom burden and its relationship to conversion timelines in American REM sleep behavior disorder cohort populations
65. Investigating the levodopa equivalent dose reduction effectiveness following adaptive deep brain stimulation programming in American adults with Parkinson’s disease and motor fluctuations
66. Analyzing the cervical dystonia botulinum toxin injection optimization — including dose, target muscle selection, and injection frequency — and its impact on treatment response in American movement disorder clinic populations
67. Developing a wearable sensor-based Parkinson’s disease motor symptom monitoring system and evaluating its accuracy for quantifying tremor, bradykinesia, and dyskinesia compared to clinical rating scales
68. Characterizing the drug-induced parkinsonism prevalence in American adults taking dopamine-blocking medications and evaluating resolution timelines following medication discontinuation
69. Investigating the monoamine oxidase B inhibitor neuroprotective potential and disease-modifying effects in American adults with early Parkinson’s disease using longitudinal biomarker and imaging outcomes
70. Analyzing the Parkinson’s disease caregiver burden patterns and its relationship to patient motor and non-motor symptom severity in American community-dwelling patient-caregiver dyads

6. Headache and Pain Neurology

Headache disorders — particularly migraine, cluster headache, and medication overuse headache — affect approximately forty-seven million Americans and represent one of the most prevalent and economically costly neurological conditions, with a recent revolution in migraine-specific preventive therapies creating important research questions about treatment optimization, biomarker-guided selection, and equitable access across American migraine populations.

71. Investigating the CGRP monoclonal antibody — erenumab, fremanezumab, galcanezumab, and eptinezumab — comparative effectiveness and treatment failure predictors in American adults with chronic migraine
72. Analyzing the medication overuse headache prevalence and detoxification outcome predictors in American adults receiving preventive migraine therapy in neurology practice settings
73. Developing a multidisciplinary headache management program for American adults with refractory chronic migraine and evaluating its outcomes compared to single-specialist neurological management
74. Characterizing the CGRP pathway biomarker levels — including serum CGRP and calcitonin gene-related peptide — and their relationship to migraine frequency and preventive therapy response in American cohorts
75. Investigating the gepant oral CGRP receptor antagonist effectiveness for acute migraine treatment in American adults with cardiovascular contraindications to triptans using a randomized trial design
76. Analyzing the migraine disability burden and preventive treatment initiation rate disparities across American racial, socioeconomic, and insurance type groups using claims and survey data
77. Developing a telehealth headache specialist consultation program for American rural adults with refractory migraine and evaluating its treatment optimization and quality of life outcomes
78. Characterizing the new daily persistent headache clinical features, diagnostic workup findings, and treatment response patterns in American adults presenting to tertiary headache centers
79. Investigating the non-invasive vagus nerve stimulation effectiveness for acute cluster headache abortion and prevention in American adults with episodic and chronic cluster headache
80. Analyzing the preventive migraine therapy adherence predictors and its relationship to migraine frequency reduction and health-related quality of life improvement in American neurology practice populations

7. Neuromuscular Disorders

Neuromuscular disorders — including amyotrophic lateral sclerosis, peripheral neuropathies, myasthenia gravis, muscular dystrophies, and inflammatory myopathies — represent a diverse group of conditions affecting the motor neuron, peripheral nerve, neuromuscular junction, and muscle, with gene therapy and RNA-based treatments beginning to transform outcomes for some conditions previously considered untreatable in American patients.

81. Investigating the gene therapy onasemnogene abeparvovec long-term motor outcome and safety data in American children with spinal muscular atrophy type one beyond five years of follow-up
82. Analyzing the nusinersen versus risdiplam comparative effectiveness for spinal muscular atrophy type two and three in American children and adults using multicenter registry outcome data
83. Developing a hereditary transthyretin amyloidosis diagnosis awareness program for American cardiologists and neurologists and evaluating its impact on timely diagnosis and patisiran therapy initiation
84. Characterizing the intravenous immunoglobulin versus subcutaneous immunoglobulin maintenance therapy comparative outcomes and patient preference in American adults with chronic inflammatory demyelinating polyneuropathy
85. Investigating the efgartigimod and rozanolixizumab complement and neonatal Fc receptor-targeted therapy outcomes in American adults with generalized myasthenia gravis refractory to standard immunotherapy
86. Analyzing the Duchenne muscular dystrophy eteplirsen and golodirsen exon-skipping therapy real-world effectiveness and dystrophin production outcomes in American boys using registry methodology
87. Developing a multidisciplinary neuromuscular disease clinic model for American adults with ALS and evaluating its impact on survival, tracheostomy decisions, and advance care planning quality
88. Characterizing the small fiber neuropathy diagnosis using skin punch biopsy and its clinical associations in American adults with idiopathic painful peripheral neuropathy
89. Investigating the diabetic peripheral neuropathy prevention through intensive glycemic control and its reversal potential following significant weight loss in American adults with type two diabetes
90. Analyzing the Lambert-Eaton myasthenic syndrome paraneoplastic versus autoimmune subtypes and amifampridine treatment outcomes in American neuromuscular clinic populations

8. Neurogenetics and Rare Neurological Diseases

Neurogenetics and rare neurological diseases represent an area of rapid scientific progress — with next-generation sequencing enabling diagnosis of previously unrecognized genetic conditions and RNA-based therapies targeting the underlying molecular defects in conditions including spinal muscular atrophy, Huntington’s disease, and hereditary transthyretin amyloidosis. This category of neurology thesis topics addresses genetic diagnosis, genotype-phenotype correlations, novel therapeutic approaches, and the health services challenges of providing specialized neurogenetic care to Americans with rare disorders.

91. Investigating the clinical whole-exome sequencing diagnostic yield in American adults with undiagnosed neurological disorders enrolled in the Undiagnosed Diseases Network and evaluating the therapeutic impact of genetic diagnosis
92. Analyzing the ataxia genetic landscape in American adults with late-onset cerebellar ataxia and evaluating whole-genome sequencing diagnostic yield beyond standard ataxia gene panel testing
93. Developing a neuromuscular genetic counseling program for American families with Duchenne muscular dystrophy and evaluating its impact on cascade genetic testing completion and family planning decisions
94. Characterizing the neurological phenotype spectrum of KCNQ2-related epilepsy in American children and evaluating the evidence for precision therapy with sodium channel blockers based on variant functional class
95. Investigating the antisense oligonucleotide therapy development pathway for rare pediatric neurological conditions in American academic centers and evaluating the compassionate use regulatory framework
96. Analyzing the lysosomal storage disease neurological manifestations and enzyme replacement therapy effectiveness in American children with Gaucher, Niemann-Pick, and Krabbe diseases
97. Developing a Friedreich ataxia multidisciplinary management program for American patients and evaluating the omaveloxolone therapy impact on neurological progression and quality of life
98. Characterizing the POLG-related mitochondrial disease spectrum in American adults and evaluating the valproate avoidance protocol effectiveness for preventing hepatotoxicity in affected patients
99. Investigating the neurofibromatosis type one MEK inhibitor selumetinib effectiveness for plexiform neurofibroma treatment in American children and evaluating long-term tumor response durability
100. Analyzing the tuberous sclerosis complex mTOR inhibitor everolimus and sirolimus effects on subependymal giant cell astrocytoma, renal angiomyolipoma, and pulmonary lymphangioleiomyomatosis in American patients

9. Neurological Intensive Care and Emergency Neurology

Neurological intensive care and emergency neurology address the acute management of life-threatening neurological conditions — including status epilepticus, acute stroke, subarachnoid hemorrhage, traumatic brain injury, and Guillain-Barré syndrome — in American neurological intensive care units and emergency departments. This category of neurology thesis topics examines acute neurological treatment protocols, neuroprotection strategies, prognostication after severe neurological injury, and the health systems design of American neurocritical care programs.

101. Investigating the targeted temperature management protocol optimization — including temperature target, cooling rate, and rewarming speed — for American adults resuscitated from out-of-hospital cardiac arrest
102. Analyzing the EEG monitoring duration and seizure detection yield in American adults with moderate to severe traumatic brain injury in neurosurgical intensive care units
103. Developing a super-refractory status epilepticus treatment algorithm for American neurological intensive care units and evaluating the comparative effectiveness of ketamine, propofol, and barbiturate coma
104. Characterizing the multimodal neuromonitoring-guided management outcomes for American adults with severe traumatic brain injury using intracranial pressure, cerebral oxygenation, and microdialysis data
105. Investigating the time to treatment and clinical outcome relationships for Guillain-Barré syndrome intravenous immunoglobulin initiation in American adults across different disease severity categories
106. Analyzing the early goal-directed therapy and hemostatic resuscitation protocol effectiveness for American adults with spontaneous intracerebral hemorrhage and coagulopathy reversal
107. Developing a withdrawal of life-sustaining treatment and goals of care communication protocol for American families of patients with devastating acute brain injury in neurological intensive care settings
108. Characterizing the post-cardiac arrest neurological prognostication accuracy of multimodal assessment — including EEG, somatosensory evoked potentials, MRI, and biomarkers — in American neurocritical care units
109. Investigating the decompressive craniectomy timing and outcomes for American adults with malignant middle cerebral artery infarction using a propensity-matched registry analysis
110. Analyzing the cerebral vasospasm detection and treatment outcomes following aneurysmal subarachnoid hemorrhage in American comprehensive stroke centers using transcranial Doppler and CT perfusion monitoring

10. Headache and Sleep Neurology

Sleep disorders with neurological implications — including REM sleep behavior disorder, narcolepsy, restless legs syndrome, and the relationship between sleep disruption and neurodegeneration — represent an important category of neurology thesis topics that addresses the bidirectional relationship between sleep and brain health in American populations.

111. Investigating the idiopathic REM sleep behavior disorder conversion rate to Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy in American cohorts using polysomnography-confirmed diagnosis
112. Analyzing the narcolepsy type one orexin deficiency mechanisms and pitolisant and solriamfetol treatment effectiveness compared to sodium oxybate in American adults with excessive daytime sleepiness
113. Developing a restless legs syndrome augmentation recognition and management protocol for American adults on dopaminergic therapy and evaluating alpha-2-delta ligand switching outcomes
114. Characterizing the sleep architecture abnormalities in American adults with early Parkinson’s disease and evaluating their relationship to cognitive trajectory and Lewy body pathology burden
115. Investigating the excessive daytime sleepiness and cognitive impairment relationships in American adults with obstructive sleep apnea and evaluating CPAP therapy reversal of neuropsychological deficits

11. Neuro-Oncology

Neuro-oncology addresses primary brain tumors — including glioblastoma, lower-grade gliomas, meningiomas, and primary central nervous system lymphoma — as well as the neurological complications of systemic cancer and cancer treatment, making this a specialized category of neurology thesis topics at American comprehensive cancer centers and academic neurology programs.

116. Investigating the IDH-mutant lower-grade glioma natural history and radiotherapy deferral criteria in American adults with molecular favorable tumor characteristics using progression-free survival as the primary endpoint
117. Analyzing the tumor treating fields device therapy adherence optimization and survival outcome associations in American adults with newly diagnosed glioblastoma receiving concurrent temozolomide chemoradiation
118. Developing a neurocognitive monitoring program for American adults receiving whole brain radiotherapy for brain metastases and evaluating memantine and hippocampal avoidance neuroprotection effectiveness
119. Characterizing the primary central nervous system lymphoma management patterns and survival outcomes in American immunocompetent adults using the national cancer database
120. Investigating the CAR-T cell therapy for recurrent glioblastoma in American adults targeting EGFRvIII and IL13Rα2 antigens and evaluating tumor antigen escape mechanisms

12. Headache, Pain, and Functional Neurological Disorders

Functional neurological disorder — formerly called conversion disorder — represents one of the most common and least well-understood conditions in American neurology, with important research questions about pathophysiology, evidence-based treatment, and the health services implications of this frequently disabling but potentially treatable condition.

121. Investigating the functional neurological disorder prevalence and clinical characteristics in American neurology clinic populations and evaluating the misdiagnosis rate and diagnostic delay from symptom onset
122. Analyzing the physical therapy-based treatment effectiveness for functional movement disorder in American adults using a randomized controlled trial design with validated motor outcome measures
123. Developing a functional neurological disorder specialty clinic model for American academic neurology centers and evaluating its diagnostic accuracy, treatment completion rates, and clinical outcome effectiveness
124. Characterizing the neurobiological mechanisms of functional neurological disorder — including predictive coding disruption and altered agency processing — using functional neuroimaging in American patient cohorts
125. Investigating the trauma exposure and adverse childhood experience burden in American adults with functional neurological disorder and evaluating trauma-focused psychotherapy integration with physical rehabilitation

13. Neuroinfectious Diseases

Neuroinfectious diseases address the neurological complications of bacterial, viral, fungal, and parasitic infections — including bacterial meningitis, viral encephalitis, neurocysticercosis, and the neurological sequelae of HIV, COVID-19, and other systemic infections — making this a clinically important category of neurology thesis topics that bridges infectious disease and neurology.

126. Investigating the long COVID neurological syndrome — including brain fog, dysautonomia, and small fiber neuropathy — prevalence and biomarker associations in American adults using prospective cohort methodology
127. Analyzing the neurocysticercosis management outcomes and seizure control rates following antihelminthic therapy and corticosteroids in American adults with parenchymal cysticercosis
128. Developing a bacterial meningitis outcomes prediction model for American adults using clinical and laboratory variables at presentation and evaluating its accuracy for early prognosis and resource allocation
129. Characterizing the viral encephalitis etiological distribution and diagnostic yield of metagenomic next-generation sequencing compared to standard testing in American neurological intensive care unit populations
130. Investigating the neurological complications of HIV — including HIV-associated neurocognitive disorder — in American adults on modern antiretroviral therapy and evaluating the impact of early treatment initiation

14. Neurological Health Disparities and Global Neurology

Neurological health disparities in the United States reflect persistent inequities in neurological disease risk, diagnosis, treatment access, and outcomes across racial, socioeconomic, and geographic lines — with important research questions about the mechanisms driving these disparities and the interventions that can reduce them across American neurology.

131. Investigating the racial disparities in Alzheimer’s disease diagnosis rates, biomarker study representation, and anti-amyloid immunotherapy access in American memory clinic and clinical trial populations
132. Analyzing the geographic variation in epilepsy surgery evaluation rates and surgical treatment utilization across American states and evaluating the relationship to regional epilepsy center availability
133. Developing a community health worker-delivered stroke risk factor management program for American Black adults with hypertension and evaluating its blood pressure control and stroke prevention outcomes
134. Characterizing the multiple sclerosis diagnosis delay patterns and their relationship to race and socioeconomic status in American adults presenting to academic neurology centers
135. Investigating the neurology workforce geographic distribution and its relationship to neurological care access quality and preventable neurological hospitalization rates across American counties

15. Neurological Rehabilitation and Recovery

Neurological rehabilitation addresses recovery from stroke, traumatic brain injury, spinal cord injury, and other acquired neurological conditions — with important research questions about the neural mechanisms of recovery, optimal rehabilitation intensity, novel interventions including noninvasive brain stimulation and robotic-assisted therapy, and the health systems factors that determine rehabilitation access for American patients with neurological disability.

136. Investigating the constraint-induced movement therapy intensity and duration optimization for improving upper extremity motor function in American adults with chronic hemiplegia following stroke
137. Analyzing the transcranial direct current stimulation augmentation of physical therapy effectiveness for motor recovery in American adults with moderate to severe stroke using a randomized sham-controlled trial design
138. Developing a community-based stroke recovery support program for American adults with residual disability and evaluating its effectiveness in maintaining functional gains and reducing secondary complications
139. Characterizing the traumatic brain injury rehabilitation intensity and outcome relationships in American inpatient rehabilitation facility populations using the Traumatic Brain Injury Model Systems database
140. Investigating the spinal cord stimulation epidural electrode placement optimization for facilitating lower extremity voluntary movement in American adults with chronic motor complete spinal cord injury

16. Emerging Neurology Frontiers

Emerging frontiers in neurology encompass the most innovative research directions — including blood-based biomarkers for neurological diagnosis, gene editing for neurological disease, closed-loop neuromodulation, and the convergence of artificial intelligence with neurological diagnosis and monitoring — creating a forward-looking category of neurology thesis topics that engages graduate students with the discoveries defining the future of American neurology.

141. Investigating the plasma phosphorylated tau 217 assay performance as a primary care-accessible Alzheimer’s disease screening tool in American adults with cognitive concerns before specialist referral
142. Analyzing the CRISPR gene editing approach for correcting the Huntington’s disease CAG repeat expansion in human iPSC-derived neurons and evaluating its efficiency and off-target editing safety
143. Developing a closed-loop responsive deep brain stimulation algorithm for Parkinson’s disease that adapts stimulation parameters to real-time local field potential biomarkers of motor state
144. Characterizing the artificial intelligence model performance for automated multiple sclerosis lesion detection and volumetric measurement from brain MRI in American radiology and neurology practice settings
145. Investigating the brain organoid model utility for recapitulating microcephaly, lissencephaly, and other cortical malformation pathophysiology for drug screening in American neurogenetics research programs
146. Analyzing the multimodal blood biomarker panel — combining neurofilament light chain, GFAP, phosphorylated tau, and amyloid-beta — for staging neurodegeneration severity in American population cohort studies
147. Developing a wearable EEG device for ambulatory seizure detection and classification in American adults with drug-resistant epilepsy and evaluating its sensitivity and false positive rate
148. Characterizing the optogenetic circuit dissection approach for identifying the neural substrates of motor circuit dysfunction in Parkinson’s disease mouse models and evaluating potential therapeutic targets
149. Investigating the exosome-based blood biomarker panel for Parkinson’s disease diagnosis and progression monitoring in American movement disorder clinic populations using proteomics methodology
150. Analyzing the artificial intelligence model performance for predicting stroke outcome and rehabilitation potential from admission MRI and clinical variables in American comprehensive stroke center populations

17. Neuroimmunology and Inflammatory Neurological Diseases

Beyond multiple sclerosis, neuroimmunology encompasses a growing range of inflammatory neurological conditions — including autoimmune encephalitis, neurosarcoidosis, CNS vasculitis, and inflammatory peripheral neuropathies — that require immunological investigation and immunotherapy management at American academic neurology and neuroimmunology programs.

151. Investigating the anti-NMDA receptor encephalitis clinical recovery predictors and long-term outcome patterns in American adults and children following first-line and second-line immunotherapy
152. Analyzing the neurosarcoidosis diagnostic criteria performance and corticosteroid versus steroid-sparing immunosuppressive therapy comparative outcomes in American academic neurology populations
153. Developing a CNS vasculitis diagnostic evaluation algorithm for American neurologists and evaluating the diagnostic yield of different investigation combinations including MRI, angiography, and brain biopsy
154. Characterizing the MOG antibody-associated disease long-term relapse patterns and prophylactic immunotherapy effectiveness in American adults compared to neuromyelitis optica spectrum disorder
155. Investigating the autoimmune epilepsy prevalence and immunotherapy response prediction using autoantibody panel testing in American adults with new-onset seizures and encephalopathy

18. Neurological Critical Care and Trauma

Traumatic brain injury affects approximately three million Americans annually — representing a major public health burden — with important research questions about neuroprotection, rehabilitation timing, long-term cognitive outcomes, and the chronic traumatic encephalopathy relationship in American contact sport athletes and military veterans.

156. Investigating the progesterone neuroprotection therapy safety and effectiveness in American adults with moderate to severe traumatic brain injury using a multicenter randomized trial design
157. Analyzing the chronic traumatic encephalopathy neuropathological findings and their relationship to repetitive head impact exposure in American contact sport athletes using postmortem brain banking data
158. Developing a concussion return-to-learn and return-to-sport protocol for American high school athletes and evaluating its adherence rates and symptomatic recovery outcome effectiveness
159. Characterizing the long-term cognitive and psychiatric outcomes of mild traumatic brain injury in American military veterans using prospective neuropsychological and neuroimaging follow-up methodology
160. Investigating the blood GFAP and neurofilament light chain biomarker performance for ruling out intracranial injury in American adults with mild traumatic brain injury and evaluating CT scan reduction potential

19. Autonomic and Peripheral Nervous System Disorders

Autonomic nervous system disorders and peripheral neuropathies represent an important and clinically underserved category of neurological disease — with important conditions including postural orthostatic tachycardia syndrome, diabetic neuropathy, and small fiber neuropathy causing significant disability in American adults.

161. Investigating the postural orthostatic tachycardia syndrome prevalence surge and pathophysiological mechanisms in American adults following COVID-19 infection using tilt table and autonomic function testing
162. Analyzing the ivabradine versus propranolol versus midodrine comparative effectiveness for postural orthostatic tachycardia syndrome symptom management in American adults
163. Developing a diabetic peripheral neuropathy screening program for American adults with type two diabetes in primary care and evaluating its effectiveness in identifying and treating early peripheral nerve dysfunction
164. Characterizing the hereditary transthyretin amyloidosis cardiac and neurological phenotype interactions and patisiran versus inotersen treatment outcome comparisons in American patients
165. Investigating the intravenous immunoglobulin versus plasma exchange comparative effectiveness for Guillain-Barré syndrome in American adults across different disease severity and timing categories

20. Neurological Pharmacology and Clinical Trials

Neurological pharmacology and clinical trials address the drug development, clinical trial methodology, and precision medicine approaches needed to advance the therapeutic armamentarium for neurological diseases — encompassing trial design innovation, biomarker endpoint development, and the regulatory science governing neurological drug approval in the United States.

166. Investigating the platform trial design advantages for Alzheimer’s disease drug development and evaluating the AHEAD study and similar platform trial efficiencies for testing multiple interventions simultaneously
167. Analyzing the FDA accelerated approval pathway utilization for neurological disease treatments and evaluating the confirmatory trial completion rates and clinical benefit verification for surrogate endpoint approvals
168. Developing a patient-reported outcome measure validation framework for neurological disease clinical trials and evaluating the content validity and measurement properties of novel endpoints in American patient populations
169. Characterizing the biomarker endpoint surrogate validity requirements for FDA approval of disease-modifying therapies for neurodegenerative diseases in American regulatory submissions
170. Investigating the adaptive enrichment trial design methodology for precision neurology studies that prospectively identify biomarker-defined patient subgroups most likely to benefit from targeted interventions

21. Neurological Nursing and Allied Health

Neurological nursing and allied health research addresses the contributions of nurses, advanced practice providers, physiotherapists, speech-language pathologists, and neuropsychologists to comprehensive neurological care — an important category of neurology thesis topics for graduate students with clinical backgrounds in neurological nursing and allied health professions.

171. Investigating the advanced practice provider-led neurology clinic model effectiveness for managing stable neurological conditions in American adults and evaluating its clinical outcome equivalence to neurologist-led care
172. Analyzing the speech-language pathologist dysphagia assessment accuracy and feeding recommendation outcomes in American adults with acute stroke using videofluoroscopic swallow study validation
173. Developing a nurse-led epilepsy self-management education program for American adults with drug-resistant epilepsy and evaluating its impact on seizure diary compliance, medication adherence, and quality of life
174. Characterizing the physiotherapist-led balance and gait rehabilitation program outcomes for American adults with Parkinson’s disease using wearable sensor objective gait analysis methodology
175. Investigating the neuropsychologist cognitive assessment contribution to epilepsy surgery candidacy evaluation in American adults with drug-resistant temporal lobe epilepsy

22. Pediatric Neurology

Pediatric neurology addresses neurological disorders in children — including neurodevelopmental conditions, childhood epilepsies, pediatric stroke, neurometabolic disorders, and the neurological sequelae of prematurity — representing a specialized and clinically important category of neurology thesis topics at American children’s hospitals and pediatric neuroscience programs.

176. Investigating the childhood arterial ischemic stroke recurrence risk factors and antithrombotic therapy comparative effectiveness in American children using the International Pediatric Stroke Study data
177. Analyzing the infantile spasm treatment response and developmental outcome predictors for ACTH versus vigabatrin versus prednisolone in American infants across different etiological categories
178. Developing a pediatric headache telemedicine consultation program for American children in rural communities and evaluating its diagnostic quality and treatment effectiveness compared to in-person evaluation
179. Characterizing the neurodevelopmental outcome trajectories in American extremely preterm infants with periventricular leukomalacia using longitudinal MRI and cognitive assessment methodology
180. Investigating the ketogenic diet long-term effectiveness and tolerability in American children with Dravet syndrome refractory to sodium channel blocker antiseizure medications

23. Neurology Health Services Research

Neurology health services research examines how neurological care is organized, financed, and delivered across American health systems — addressing care quality measurement, neurologist workforce issues, teleneurology, and the policy frameworks shaping neurological care access and outcomes for American patients.

181. Investigating the neurologist workforce shortage impact on neurological care access quality and preventable neurological hospitalization rates across American rural and underserved communities
182. Analyzing the teleneurology consultation program effectiveness for improving epilepsy management quality in American community neurology practices without subspecialty epilepsy expertise
183. Developing a value-based neurology care model for American health systems managing high-cost neurological conditions and evaluating its impact on care quality and total cost measurement
184. Characterizing the multiple sclerosis disease-modifying therapy prescribing patterns and adherence rates across American neurology practice types and evaluating their relationship to relapse and disability outcomes
185. Investigating the Parkinson’s disease quality measure performance and its relationship to patient outcomes across American neurology practices participating in the Parkinson’s Foundation Quality Improvement Initiative
186. Analyzing the Medicare Advantage versus traditional Medicare neurological care access and outcome differences for American adults with stroke, epilepsy, and Parkinson’s disease
187. Developing a quality improvement collaborative for American comprehensive stroke centers focused on reducing door-to-needle time variability and evaluating its learning system effectiveness
188. Characterizing the neurological disease financial toxicity burden and its health behavior consequences for American adults with multiple sclerosis, epilepsy, and Parkinson’s disease
189. Investigating the neurology consultation service model impact on inpatient neurological care quality and length of stay in American academic medical centers using interrupted time series methodology
190. Analyzing the direct-to-consumer neurological supplement and unproven therapy utilization patterns and safety concerns in American adults with neurological conditions using national survey and adverse event data

24. Neuroimaging and Neurophysiology

Neuroimaging and neurophysiology provide the diagnostic infrastructure of modern American neurology — with MRI, PET, EEG, and evoked potentials enabling increasingly precise characterization of structural, functional, and metabolic nervous system pathology. This category of neurology thesis topics addresses novel imaging biomarkers, neurophysiological monitoring applications, and the artificial intelligence-assisted analysis of neurological diagnostic data.

191. Investigating the quantitative MRI relaxometry technique performance for detecting early white matter abnormalities in American adults with cerebral small vessel disease before conventional MRI lesion development
192. Analyzing the tau PET imaging staging system reliability and clinical utility for treatment selection in American adults with suspected Alzheimer’s disease at memory disorder programs
193. Developing an automated EEG seizure detection algorithm using convolutional neural networks and evaluating its sensitivity and false positive rate in American neurology intensive care unit populations
194. Characterizing the functional MRI language lateralization accuracy compared to Wada testing for presurgical epilepsy evaluation in American adults with temporal lobe epilepsy
195. Investigating the quantitative susceptibility mapping MRI technique for detecting substantia nigra iron deposition as a Parkinson’s disease biomarker in American movement disorder research cohorts
196. Analyzing the magnetoencephalography source localization accuracy for epileptic spike mapping in American adults with drug-resistant focal epilepsy undergoing presurgical evaluation
197. Developing a diffusion tensor imaging tractography protocol for mapping corticospinal tract integrity in American adults with motor neuron disease and evaluating its utility for disease staging
198. Characterizing the resting-state fMRI default mode network connectivity patterns and their relationship to cognitive impairment severity across the Alzheimer’s disease clinical continuum in American cohorts
199. Investigating the portable EEG device performance for ambulatory seizure monitoring in American adults with drug-resistant epilepsy and evaluating its clinical utility for seizure diary accuracy improvement
200. Analyzing the positron emission tomography amyloid and tau imaging concordance with plasma biomarker levels in American adults with mild cognitive impairment for Alzheimer’s disease staging

The Range of Neurology Thesis Topics

Current Issues

The Alzheimer’s disease treatment revolution has arrived — with lecanemab and donanemab becoming the first treatments to demonstrate slowing of clinical decline in early symptomatic Alzheimer’s disease by clearing amyloid plaques — yet their clinical implementation in American neurology and memory care practice is generating complex and unresolved questions about patient selection, safety monitoring, equitable access, and healthcare system capacity. The ARIA — amyloid-related imaging abnormalities — safety monitoring requirements demand serial MRI imaging that strains American radiology capacity, the treatment costs exceed one hundred thousand dollars annually raising profound insurance access questions, and the representation of American Black and Hispanic patients in pivotal trials was inadequate to determine whether these therapies are equally effective across racial groups. Graduate students developing neurology thesis topics that address anti-amyloid therapy implementation, safety monitoring optimization, equity of access, and biomarker-guided patient selection contribute to the most clinically consequential and practically urgent research agenda in contemporary American neurology.

The neurological consequences of COVID-19 — collectively termed long COVID neurological syndrome — have created a new category of neurological disease affecting millions of Americans, with brain fog, dysautonomia, small fiber neuropathy, and accelerated cognitive aging representing poorly understood conditions for which American neurology currently lacks evidence-based treatments. The postural orthostatic tachycardia syndrome surge in American young adults following COVID-19 infection has overwhelmed autonomic neurology practices, the post-COVID cognitive impairment burden is generating enormous demand for neuropsychological evaluation and neurorehabilitation services, and the neurobiological mechanisms driving these conditions — including persistent neuroinflammation, vascular endothelial dysfunction, and autoimmune dysregulation — are being actively investigated at American academic neurology centers. Research addressing long COVID neurology represents one of the most urgent and scientifically novel frontiers available to graduate students in neurology.

The neurological disease precision medicine revolution — enabled by disease-specific biomarkers, genetic diagnostics, and molecular therapies targeting the underlying disease mechanisms — is transforming several neurological conditions from symptom management to disease modification, while simultaneously raising profound equity concerns about who benefits from expensive precision neurological therapies. The approval of gene therapies for spinal muscular atrophy, antisense oligonucleotides for Huntington’s disease and hereditary transthyretin amyloidosis, and the emerging pipeline of RNA-based therapies for neurological diseases creates both extraordinary clinical opportunities and urgent policy questions about how American payers and health systems will finance highly expensive but potentially curative neurological therapies for rare and common conditions alike.

Recent Trends

Blood-based biomarkers for neurological diagnosis have advanced at extraordinary speed — moving from experimental research tools to clinical laboratory tests capable of detecting Alzheimer’s disease pathology, measuring neurodegeneration severity, and monitoring neurological disease activity from a simple blood draw. Plasma phosphorylated tau 217, the p-tau181/amyloid-beta ratio, neurofilament light chain, and GFAP are demonstrating diagnostic accuracy approaching cerebrospinal fluid and PET imaging reference standards across Alzheimer’s disease, multiple sclerosis, traumatic brain injury, and other neurological conditions. The clinical implementation of blood-based neurological biomarkers in American primary care and neurology practice represents a major health services research frontier — with questions about how these tests should be ordered and interpreted, what clinical actions should follow abnormal results, and how equitable access to biomarker-guided neurological care can be ensured across diverse American populations.

Neuromodulation has become an increasingly central therapeutic modality in American neurology — with deep brain stimulation indications expanding beyond Parkinson’s disease to include essential tremor, dystonia, epilepsy, and OCD, focused ultrasound offering incision-free thalamotomy and deep brain targets, responsive neurostimulation providing closed-loop seizure control, and transcranial magnetic stimulation treating migraine and depression with neurological comorbidity. The convergence of closed-loop neuromodulation with artificial intelligence — enabling systems that adapt stimulation parameters in real time to brain state biomarkers — represents one of the most technically exciting frontiers in neurology research, with American academic neurology and biomedical engineering programs actively developing next-generation adaptive neuromodulation systems that could transform the treatment of movement disorders, epilepsy, and pain.

Future Directions

Gene and RNA therapy for neurological diseases represents the most transformative therapeutic frontier in contemporary American neurology — with proof-of-concept successes in spinal muscular atrophy, hereditary transthyretin amyloidosis, and X-linked adrenoleukodystrophy demonstrating that precisely targeting the molecular defect of a genetic neurological disease can produce extraordinary clinical benefits. Future neurology thesis topics will evaluate the extension of gene and RNA therapy approaches to more common neurological diseases — including Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and epilepsy — investigate the central nervous system delivery challenges including blood-brain barrier penetration and neuronal transduction efficiency, and address the equity implications of ensuring that gene therapy access reaches American patients regardless of their socioeconomic status or geographic proximity to academic neurology centers capable of administering these complex treatments.

The digital neurology future — where continuous wearable monitoring, passive smartphone sensing, and home-based cognitive and motor assessment provide neurologists with real-world biomarker streams between clinic visits — represents a second transformative direction that will fundamentally change how American neurologists understand disease progression and treatment response in their patients’ daily lives. Future neurology thesis topics will develop and validate wearable sensor algorithms for continuous motor symptom quantification in Parkinson’s disease, automated seizure detection in epilepsy, and gait and balance monitoring in multiple sclerosis — while simultaneously addressing the clinical workflow integration challenges of translating continuous remote neurological monitoring data into actionable clinical decisions for American neurologists managing large patient panels. Graduate students who combine neurological expertise with biomedical engineering and data science skills will be uniquely positioned to lead this digital neurology research agenda.

Conclusion

The 200 neurology thesis topics presented across these twenty-four categories reflect the extraordinary breadth of a discipline that spans stroke and epilepsy, neurodegeneration and neuroimmunology, movement disorders and neuromuscular disease, neurogenetics and rare disorders, neurological critical care and rehabilitation, pediatric neurology and geriatric neurology, and the emerging frontiers of blood-based biomarkers, gene therapy, closed-loop neuromodulation, and digital neurology. Students pursuing neurology thesis topics at American universities engage with research questions of profound biological complexity and immediate human consequence — questions whose answers will determine whether the transformative therapeutic advances of the past decade in neurological disease reach all Americans who need them, whether the biological basis of conditions like Alzheimer’s disease and ALS can be modified before devastating clinical disease develops, and whether the next generation of American patients with neurological disorders experiences a world where precision medicine has transformed even the most challenging brain diseases. Career pathways extend into academic neurology, pharmaceutical neurological drug development, biotechnology, health policy, global neurology, and the technology companies developing digital health tools for neurological monitoring — all domains where rigorously trained neurology scholars make lasting contributions to reducing the burden of neurological disease in America.

Academic Support

iResearchNet provides expert academic support for graduate students developing neurology thesis topics across the full spectrum of this discipline’s biological, clinical, epidemiological, and health policy dimensions. Our consultants bring specialized expertise in cerebrovascular disease, epilepsy, neurodegeneration, multiple sclerosis and neuroimmunology, movement disorders, headache, neuromuscular disease, neurogenetics, neurocritical care, neurological rehabilitation, neuro-oncology, pediatric neurology, neurological health disparities, neuroimaging, and neurophysiology — with direct experience supporting students in American neurology residency research programs, neuroscience doctoral training, clinical research fellowships, and health services research programs focused on neurological care quality and access. Whether you are designing a clinical trial for a neurological disease-modifying therapy, analyzing neuroimaging biomarker data from a multi-site cohort, developing a stroke systems of care evaluation, building a neurological health disparities research program, or investigating the outcomes of a novel neuromodulation approach, iResearchNet’s support is oriented toward strengthening your scholarly development and deepening your engagement with neurology as a research discipline. Our mission is to support your intellectual growth, not to substitute for the original thinking that defines excellent graduate scholarship in neurology.